Article · Journal · 2024

PRELIMINARY RESULTS FROM A MULTICENTER PHASE 2/3 STUDY OF NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR OSIVELOTOR (GBT021601) FOR THE TREATMENT OF PATIENTS WITH SICKLE CELL DISEASE

Hematology Transfusion and Cell Therapy

Citations: 3from other works
Field-weighted impact: 0.791.00 is the world average for its field and year
Among its field: 73rd percentileby citations, against works of its field and year
Authors: 10from 8 institutions

Authors

10 authors across 8 institutions in 2 countries